Preparing for the 2025 Influenza Season: Key Insights for Pharmacists
Understanding NIP Stock and Vaccine Recommendations
The National Immunisation Program (NIP) plays a crucial role in protecting vulnerable populations from influenza. In 2025, deliveries of NIP stock are anticipated around late March. Pharmacists are advised to guide older patients, especially those 65 years and older, to wait for these specific NIP-funded vaccines, such as Fluad Quad 0.50 mL or Fluzone High-Dose Quadrivalent. These adjuvanted vaccines are designed to elicit a stronger immune response, offering better protection against flu-related hospitalizations and severe outcomes.
One Dose Suffices: Nuances for the 2025 Season
For most individuals, a single dose of the influenza vaccine suffices, as optimal protection lasts about 3–4 months. While the vaccine’s effectiveness may wane after this period, exceptions exist. For instance, children under 9 years receiving their first flu shot or immigrants post-transplant may require a second dose. Additionally, those traveling to flu-prone regions may benefit from an extra dose, especially considering the 2024 to 2025 formulation updates.
Timing is Everything: Best Practices Before Flu Season
With the Australian influenza season peaking in August, preemptive vaccination is crucial. The 2025 flu season is expected to be significant, with confirmed cases already exceeding previous records. Flu vaccines should ideally be administered before the season starts, generally from May.
The Promise of Combined Vaccines
The future is promising with the development of combined vaccines. In 2024, Moderna announced promising results from their clinical trials on an mRNA-based combination vaccine for influenza and COVID-19. Similarly, trials from Pfizer and BioNTech are ongoing, while Novavax conducts tests on non-mRNA versions. For now, co-administration of influenza and COVID-19 vaccines remains advisable for at-risk groups.
Expanded NIP Funding: A Broader Shield
The NIP continues to support at-risk groups, including seniors, Indigenous populations, and pregnant individuals. Notably, the cell-based vaccine Flucelvax Quad is now accessible under NIP for those aged 5-64 with increased flu risks, expanding protective measures.
Pro Tip
Stay updated with webinars like the PSA member briefing on ATAGI 2025 seasonal influenza vaccination advice. Such events are invaluable for healthcare professionals looking to enhance their knowledge and offer informed patient guidance.
Frequently Asked Questions About the 2025 Influenza Season
Q: Should older adults wait for the NIP vaccine?
A: Yes, they should wait for the arrival of NIP stock for the most effective protection using adjuvanted vaccines.
Q: Is a second influenza vaccine dose necessary?
A: For most patients, one dose is sufficient. Second doses may be necessary for specific groups, including young children and immunocompromised individuals.
Expanding Horizons: Future Trends in Influenza Vaccination
The landscape for influenza vaccination is evolving, with advancing technologies promising more comprehensive solutions. Co-administration practices, expanded NIP funding, and new vaccine formulations are pivotal trends that will likely continue post-2025. As we move forward, continued research and collaboration among global health organizations will be essential to safeguard public health during flu seasons.
Did You Know?
Influenza vaccination significantly reduces the incidence of flu-related hospitalizations, especially among vulnerable demographics such as seniors and young children.
Engage Further
We invite you to comment below with your experiences and insights on navigating flu season preparations. Don’t forget to explore our other articles for more valuable healthcare information, and subscribe to our newsletter for the latest updates.
